Compare CWT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | SRPT |
|---|---|---|
| Founded | 1926 | 1980 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 1997 | 2000 |
| Metric | CWT | SRPT |
|---|---|---|
| Price | $45.55 | $22.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 28 |
| Target Price | ★ $54.50 | $25.40 |
| AVG Volume (30 Days) | 361.7K | ★ 3.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | $963,695,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $10.38 | N/A |
| Revenue Next Year | $5.80 | N/A |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | 6.41 | ★ 15.58 |
| 52 Week Low | $41.29 | $10.42 |
| 52 Week High | $51.23 | $64.80 |
| Indicator | CWT | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 62.96 |
| Support Level | $44.23 | $20.61 |
| Resistance Level | $46.78 | $23.51 |
| Average True Range (ATR) | 1.02 | 1.27 |
| MACD | 0.15 | 0.58 |
| Stochastic Oscillator | 78.75 | 77.18 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.